To Lead, We Must Act Now - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

To Lead, We Must Act Now


Pharmaceutical Technology


Angie Drakulich
While recapping the past 30 years' innovations in pharmaceutical technology, it's also important to start preparing for the next 30 years. But staying ahead of the curve will be challenging.

Take the recent report issued by the HealthCare Institute of New Jersey. According to the report, there is a striking disparity in the state between high-demand occupations in the pharmaceutical and medical technology industries and the number of qualified workers to fill those positions. Modest job growth in this field is expected for the next four years, according to the report.

Adding to the overall problem are the low numbers of college students graduating with degrees in the subjects needed to work in these industries. Washington acknowledged this gap in April when both the House and Senate passed bills in support of the President's 2006 American Competitiveness Initiative, which aims to improve education and research in science, technology, engineering, and math (STEM).

H.R.362 targets training, grant programs, and scholarships for teachers and students in STEM disciplines, while a second House bill, H.R.363, targets graduate fellowships and early-career researcher grants. The Senate bill (S.761) would raise appropriations for math- and science-related federal agencies and innovation projects in STEM fields. S.761 would also encourage collaboration among agencies and higher education institutions.

Every day, students demonstrate their core role in the industry. In May, for example, a Weill Cornell Medical College group helped place the heart disease drug simvastatin on the World Health Organization's list of essential medicines.

Going forward, it is in our national interest to pay attention to and support these students. The alternative—standing by while other nations take the lead on issues such as embryonic stem cell research and gene therapy—is simply not the American way, nor the path we want to set for the generations to come.











Angie Drakulich is the managing editor of Pharmaceutical Technology,

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here